Societies and non-profits at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

42 societies and non-profits are at ESMO 2026 — 43 presentations on the program and 13 with a booth in the exhibit hall. Most represented: World Health Organization (4 on the program), Latin American Cooperative Oncology Group (2 on the program), Cancer Patients Europe (2 on the program). 16 of them have their own page in this guide. As of Sep 29, 2026.

All 736 organizations at ESMO 2026 →

Showing 1–9 of 42 organizations

Organization	ESMO 2026 Attendance
World Health Organization Geneva, Switzerland
who.int Society & non-profit United Nations agency for international public health, based in Geneva, Switzerland.	Talk Fri Oct 23 16:35–16:55 Modelling economic impact to deliver population health impact The exorbitant costs of cancer care: What can we do? Talk Sat Oct 24 10:35–10:55 Building and evaluating a sustainable cancer priority setting system in ESMO-WHO-IARC collaboration in global cancer control Talk Sat Oct 24 10:55–11:15 Cancer workforce crisis: Building solutions ESMO-WHO-IARC collaboration in global cancer control Chair Sat Oct 24 14:45–16:15 Rapid oral: Policy with Brazilian National Cancer Institute (INCA), Mahatma Gandhi Medical College and Hospital Abstract Sat Oct 24 15:52–16:07 Invited Discussant 3321RO, 3322RO, 3323RO and 3324RO Rapid oral: Policy Chair Sun Oct 25 08:30–10:00 Cancer care in humanitarian settings with King's College London Talk Sun Oct 25 08:50–09:10 Towards solution: Designing policy to inform action Cancer care in humanitarian settings
LA Latin American Cooperative Oncology Group Porto Alegre, Brazil
Society & non-profit Nonprofit academic cooperative group that designs and runs cancer clinical trials across Latin America, based in Porto Alegre, Brazil.	Abstract Fri Oct 23 16:25–16:30 539RO - Patient-Reported Outcomes (PROs) From DESTINY-Breast05: Health-Related Quality of Life (HRQoL) With Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients (Pts) With High-Risk HER2-Positive Early Breast Cancer (eBC) Rapid oral: Breast cancer, early stage Breast cancer Talk Sat Oct 24 16:30–16:45 How can we incorporate combination strategies in early drug development? Novel concepts for metastatic breast cancer: Looking to the future Breast cancerBiomarkers & precision oncology Chair Sat Oct 24 16:30–18:00 Novel concepts for metastatic breast cancer: Looking to the future with Peter MacCallum Cancer Centre Breast cancerBiomarkers & precision oncology Satellite Sat Oct 24 18:55–19:05 Interactive panel discussion Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute Breast cancer Satellite Sat Oct 24 19:05–19:20 Rethinking Metastatic Breast Cancer: Endocrine Sensitivity, Biomarkers, and the Role of Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction Breast cancer Satellite Sat Oct 24 19:20–19:30 Interactive panel discussion Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute Breast cancer Satellite Sat Oct 24 19:40–19:50 Interactive panel discussion Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction · with Evangelische Kliniken Essen-Mitte, Dana-Farber Cancer Institute Breast cancer Talk Sun Oct 25 10:15–10:45 Metastatic breast cancer: Case presentation & Discussion ESMO Clinical Practice Guidelines 2 · with Sestre milosrdnice University Hospital Centre Breast cancerGenitourinary cancers Satellite Sun Oct 25 18:30–20:00 Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers Satellite Sun Oct 25 18:30–18:35 Welcome and Introduction Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers Satellite Sun Oct 25 18:35–19:00 Clinical Foundation: Building and Broadening the Role of ADCs in Metastatic Breast Cancer Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers Satellite Sun Oct 25 19:45–20:00 Connecting Experience, Potential, and Future Frontiers: Panel discussion and audience Q&A Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions · with University of California San Diego, University Hospitals Leuven Breast cancerGynaecological cancers
Cancer Patients Europe Brussels, Belgium
cancerpatientseurope.org Society & non-profit Patient advocacy organisation in Brussels representing cancer patients, survivors and carers in European health policy.	Satellite Sat Oct 24 12:40–12:50 Current experience of patients receiving SC IOs Merck - Oncology Nursing Perspectives on Subcutaneous Immunotherapy: Practical Considerations for Patient Care Nursing & supportive care Talk Sun Oct 25 09:45–09:55 CN35 - Nutrition in Cancer Care: Closing the Gap Between Awareness and Action Supportive care and symptom management Nursing & supportive care Abstract Sun Oct 25 11:03–11:13 3315O - When Overall Survival Is Not Enough: The Emerging Need for Context-Sensitive Endpoint Frameworks in Oncology Proffered paper: Policy
Digestive Cancers Europe (DiCE) Brussels, Belgium
digestivecancers.eu Society & non-profit European umbrella organisation of patient groups for colorectal and other digestive cancers, based in Brussels, Belgium.	Chair Sun Oct 25 16:30–18:00 Extending life, realizing potential: Bridging innovation and implementation in cancer care with Blodcancerforum Talk Sun Oct 25 17:15–17:30 Patient testimony Extending life, realizing potential: Bridging innovation and implementation in cancer care Talk Mon Oct 26 15:25–15:45 The patient perspective on the use of CPG in the cancer continuum How can the use of ESMO's Clinical Practice Guidelines (CPG) help drive standards of care?
International Agency for Research on Cancer (IARC) Lyon, France
iarc.who.int Society & non-profit Cancer research agency of the World Health Organization in Lyon, France, studying the causes of cancer and how to prevent it.	Chair Sat Oct 24 10:15–11:45 ESMO-WHO-IARC collaboration in global cancer control with Centre Léon Bérard Talk Sat Oct 24 10:15–10:35 Global perspectives from WHO-IARC ESMO-WHO-IARC collaboration in global cancer control Talk Sat Oct 24 11:15–11:35 How to set priorities for research ESMO-WHO-IARC collaboration in global cancer control
Youth Cancer Europe Cluj-Napoca, Romania
youthcancereurope.org Society & non-profit European network of young people with cancer and young survivors, based in Cluj-Napoca, Romania, advocating for better care and research.	Talk Sat Oct 24 14:15–14:30 Meeting young people where they are: Rethinking cancer awareness ESMO - EONS Collaborative session: Policy development to reduce diagnostic delay in young people up to 39 Talk Sat Oct 24 14:30–14:40 Young onset cancers: Experiences of a young person ESMO - EONS Collaborative session: Policy development to reduce diagnostic delay in young people up to 39
Europa Uomo Antwerpen, Belgium
europa-uomo.org Society & non-profit European coalition of prostate cancer patient groups, based in Antwerp, Belgium, that campaigns for patients' interests.	Satellite Sun Oct 25 18:35–18:45 Similar Pathways, Individual Journeys: Exploring Current Experiences and Unmet Needs in the mCRPC Patient Journey PeerVoice - Navigating the Changing Landscape of 10 mCRPC Management: Reviewing Roads Travelled and Exploring Emerging Directions Genitourinary cancers Satellite Sun Oct 25 19:10–19:30 Placing Data into Practice: What Constitutes Contemporary Best Practice Approaches Upon Progression to mCRPC? PeerVoice - Navigating the Changing Landscape of 10 mCRPC Management: Reviewing Roads Travelled and Exploring Emerging Directions · with Cliniques universitaires Saint-Luc, Oncology Institute of Southern Switzerland (IOSI) Genitourinary cancers Satellite Sun Oct 25 19:30–19:45 Partnering With Our Patients Across Their mCRPC Journey: Considerations Beyond Initial Treatment Selection PeerVoice - Navigating the Changing Landscape of 10 mCRPC Management: Reviewing Roads Travelled and Exploring Emerging Directions · with Cliniques universitaires Saint-Luc, Oncology Institute of Southern Switzerland (IOSI) Genitourinary cancers Satellite Sun Oct 25 19:45–19:55 Questions and Answers Session: Expert Insights for Your Compelling Questions PeerVoice - Navigating the Changing Landscape of 10 mCRPC Management: Reviewing Roads Travelled and Exploring Emerging Directions · with Cliniques universitaires Saint-Luc, Oncology Institute of Southern Switzerland (IOSI) Genitourinary cancers
SH Spanish Head and Neck Cancer Group (TTCC) Madrid, Spain
Society & non-profit Spanish cooperative group that runs clinical trials and research in head and neck cancer.	Chair Sun Oct 25 10:15–11:30 Evolving treatment paradigms in nasopharyngeal carcinoma with National Cancer Centre Singapore Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 10:15–10:20 Presentation of case/condition Evolving treatment paradigms in nasopharyngeal carcinoma Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 14:45–16:15 Rapid oral: Head and neck cancer with The Chinese University of Hong Kong, Humanitas Research Hospital Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 15:54–16:06 Invited Discussant LBA47, 1538RO and 1541RO Rapid oral: Head and neck cancer Sarcoma, CNS, head & neck and rare cancers
Canadian Cancer Trials Group Kingston, Canada
ctg.queensu.ca Society & non-profit Academic cooperative group that designs and runs cancer clinical trials across Canada, based in Kingston, Ontario.	Talk Fri Oct 23 17:00–17:15 Real-world data: The bridge between science and practice Raising the bar for tumor-agnostic studies Biomarkers & precision oncology Talk Sun Oct 25 12:00–12:15 The role of exercise What oncologists should know about non-pharmaceutical interventions Nursing & supportive care Chair Sun Oct 25 12:00–12:50 What oncologists should know about non-pharmaceutical interventions with Oslo University Hospital, Memorial Sloan Kettering Cancer Center Nursing & supportive care